Emerging Technologies for Low‐Cost, Rapid Vaccine Manufacture,Biotechnology Journal

当前位置： X-MOL 学术 › Biotechnol. J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Emerging Technologies for Low‐Cost, Rapid Vaccine Manufacture
Biotechnology Journal ( IF 3.2 ) Pub Date : 2018-12-10 , DOI: 10.1002/biot.201800376
Zoltán Kis ₁ , Robin Shattock ₂ , Nilay Shah ₁ , Cleo Kontoravdi ₁

Affiliation

To stop the spread of future epidemics and meet infant vaccination demands in low‐ and middle‐income countries, flexible, rapid and low‐cost vaccine development and manufacturing technologies are required. Vaccine development platform technologies that can produce a wide range of vaccines are emerging, including: a) humanized, high‐yield yeast recombinant protein vaccines; b) insect cell‐baculovirus ADDomer vaccines; c) Generalized Modules for Membrane Antigens (GMMA) vaccines; d) RNA vaccines. Herein, existing and future platforms are assessed in terms of addressing challenges of scale, cost, and responsiveness. To assess the risk and feasibility of the four emerging platforms, the following six metrics are applied: 1) technology readiness; 2) technological complexity; 3) ease of scale‐up; 4) flexibility for the manufacturing of a wide range of vaccines; 5) thermostability of the vaccine product at tropical ambient temperatures; and 6) speed of response from threat identification to vaccine deployment. The assessment indicated that technologies in the order of increasing feasibility and decreasing risk are the yeast platform, ADDomer platform, followed by RNA and GMMA platforms. The comparative strengths and weaknesses of each technology are discussed in detail, illustrating the associated development and manufacturing needs and priorities.

中文翻译：

低成本，快速疫苗生产的新兴技术

为了阻止未来流行病的传播并满足中低收入国家的婴儿疫苗接种需求，需要灵活，快速和低成本的疫苗开发和制造技术。可以生产多种疫苗的疫苗开发平台技术正在兴起，包括：a）人源化，高产酵母重组蛋白疫苗；b）昆虫细胞杆状病毒ADDomer疫苗; c）膜抗原（GMMA）疫苗通用模块；d）RNA疫苗。在本文中，根据解决规模，成本和响应能力方面的挑战对现有和未来平台进行了评估。为了评估这四个新兴平台的风险和可行性，应用了以下六个指标：1）技术就绪性；2）技术复杂性；3）易于扩展；4）灵活生产各种疫苗；5）疫苗产品在热带环境温度下的热稳定性；6）从威胁识别到疫苗部署的响应速度。评估表明，以增加可行性和降低风险的顺序排列的技术是酵母平台，ADDomer平台，其次是RNA和GMMA平台。详细讨论了每种技术的相对优势和劣势，阐明了相关的开发和制造需求以及优先级。ADDomer平台，其次是RNA和GMMA平台。详细讨论了每种技术的相对优势和劣势，阐明了相关的开发和制造需求以及优先级。ADDomer平台，其次是RNA和GMMA平台。详细讨论了每种技术的相对优势和劣势，阐明了相关的开发和制造需求以及优先级。

更新日期：2018-12-10

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南